Targeted Alpha Therapy for Chronic Lymphocytic Leukaemia and Non-Hodgkin's Lymphoma with the Anti-CD37 Radioimmunoconjugate 212Pb-NNV003

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 Mar 19

PMID 32187209

Citations 17

Authors

Astri Fjelde Maaland

Amal Saidi

Julien Torgue

Helen Heyerdahl

Tania A Rozgaja Stallons

Arne Kolstad

Jostein Dahle

Affiliations

Soon will be listed here.

Abstract

Relapse of chronic lymphocytic leukaemia and non-Hodgkin's lymphoma after standard of care treatment is common and new therapies are needed. The targeted alpha therapy with 212Pb-NNV003 presented in this study combines cytotoxic α-particles from 212Pb, with the anti-CD37 antibody NNV003, targeting B-cell malignancies. The goal of this study was to explore 212Pb-NNV003 for treatment of CD37 positive chronic lymphocytic leukaemia and non-Hodgkin's lymphoma in preclinical mouse models.An anti-proliferative effect of 212Pb-NNV003 was observed in both chronic lymphocytic leukaemia (MEC-2) and Burkitt's lymphoma (Daudi) cells in vitro. In biodistribution experiments, accumulation of 212Pb-NNV003 was 23%ID/g and 16%ID/g in Daudi and MEC-2 tumours 24 h post injection. In two intravenous animal models 90% of the mice treated with a single injection of 212Pb-NNV003 were alive 28 weeks post cell injection. Median survival times of control groups were 5-9 weeks. There was no significant difference between different specific activities of 212Pb-NNV003 with regards to therapeutic effect or toxicity. For therapeutically effective activities, a transient haematological toxicity was observed. This study shows that 212Pb-NNV003 is effective and safe in preclinical models of CD37 positive chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, warranting future clinical testing.

Citing Articles

Antigen targeting and anti-tumor activity of a novel anti-CD146 Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma.

Lindland K, Malenge M, Li R, Wouters R, Bonsdorff T, Juzeniene A Sci Rep. 2024; 14(1):25941.

PMID: 39472474 PMC: 11522520. DOI: 10.1038/s41598-024-76778-z.

Preclinical Investigation of [Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model.

Saidi A, Stallons T, Wong A, Torgue J J Nucl Med. 2024; 65(11):1769-1775.

PMID: 39327021 PMC: 11533912. DOI: 10.2967/jnumed.124.268101.

Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.

Gonzalez-Kozlova E, Huang H, Jagede O, Tuballes K, Del Valle D, Kelly G Cancer Res Commun. 2024; 4(7):1726-1737.

PMID: 38934093 PMC: 11247952. DOI: 10.1158/2767-9764.CRC-24-0252.

Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin's lymphoma.

Goto H, Shiraishi Y, Okada S Explor Target Antitumor Ther. 2024; 5(1):208-224.

PMID: 38464386 PMC: 10918239. DOI: 10.37349/etat.2024.00213.

Cure of Disseminated Human Lymphoma with [Ac]Ac-Ofatumumab in a Preclinical Model.

Longtine M, Shim K, Hoegger M, Benabdallah N, Abou D, Thorek D J Nucl Med. 2023; 64(6):924-931.

PMID: 37024304 PMC: 10241019. DOI: 10.2967/jnumed.122.265167.

References

Reddy N, Ong G, Behr T, Sharkey R, Goldenberg D, Mattes M . Rapid blood clearance of mouse IgG2a and human IgG1 in many nude and nu/+ mouse strains is due to low IgG2a serum concentrations. Cancer Immunol Immunother. 1998; 46(1):25-33. PMC: 11037377. DOI: 10.1007/s002620050456. View

Fulop G, Phillips R . The scid mutation in mice causes a general defect in DNA repair. Nature. 1990; 347(6292):479-82. DOI: 10.1038/347479a0. View

Su F, Beaumier P, Axworthy D, Atcher R, Fritzberg A . Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. Nucl Med Biol. 2005; 32(7):741-7. DOI: 10.1016/j.nucmedbio.2005.06.009. View

Milenic D, Baidoo K, Kim Y, Barkley R, Brechbiel M . Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab. Transl Oncol. 2017; 10(4):535-545. PMC: 5458064. DOI: 10.1016/j.tranon.2017.04.004. View

Back T, Haraldsson B, Hultborn R, Jensen H, Johansson M, Lindegren S . Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice. Cancer Biother Radiopharm. 2009; 24(6):649-58. DOI: 10.1089/cbr.2009.0628. View

Heider K, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E . A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood. 2011; 118(15):4159-68. PMC: 3204733. DOI: 10.1182/blood-2011-04-351932. View

Milenic D, Garmestani K, Brady E, Albert P, Ma D, Abdulla A . Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm. 2005; 20(5):557-68. DOI: 10.1089/cbr.2005.20.557. View

Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow O . Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med. 1998; 38(12):1944-50. View

Beckwith K, Frissora F, Stefanovski M, Towns W, Cheney C, Mo X . The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014; 28(7):1501-10. PMC: 4090271. DOI: 10.1038/leu.2014.32. View

10.

Dekkers G, Bentlage A, Stegmann T, Howie H, Lissenberg-Thunnissen S, Zimring J . Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs. 2017; 9(5):767-773. PMC: 5524164. DOI: 10.1080/19420862.2017.1323159. View

11.

Rezvani A, Maloney D . Rituximab resistance. Best Pract Res Clin Haematol. 2011; 24(2):203-16. PMC: 3113665. DOI: 10.1016/j.beha.2011.02.009. View

12.

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M . Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v78-84. DOI: 10.1093/annonc/mdv303. View

13.

Randi A, Smith K, Castaman G . von Willebrand factor regulation of blood vessel formation. Blood. 2018; 132(2):132-140. PMC: 6182264. DOI: 10.1182/blood-2018-01-769018. View

14.

Maaland A, Heyerdahl H, OShea A, Eiriksdottir B, Pascal V, Andersen J . Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate Lu-NNV003. Eur J Nucl Med Mol Imaging. 2019; 46(11):2311-2321. PMC: 6717602. DOI: 10.1007/s00259-019-04417-1. View

15.

Gudkov S, Shilyagina N, Vodeneev V, Zvyagin A . Targeted Radionuclide Therapy of Human Tumors. Int J Mol Sci. 2016; 17(1). PMC: 4730279. DOI: 10.3390/ijms17010033. View

16.

Dennler P, Chiotellis A, Fischer E, Bregeon D, Belmant C, Gauthier L . Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug Chem. 2014; 25(3):569-78. DOI: 10.1021/bc400574z. View

17.

Nemzek J, Bolgos G, Williams B, Remick D . Differences in normal values for murine white blood cell counts and other hematological parameters based on sampling site. Inflamm Res. 2001; 50(10):523-7. DOI: 10.1007/PL00000229. View

18.

Meredith R, Torgue J, Rozgaja T, Banaga E, Bunch P, Alvarez R . Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol. 2016; 41(7):716-721. PMC: 5449266. DOI: 10.1097/COC.0000000000000353. View

19.

Kasten B, Oliver P, Kim H, Fan J, Ferrone S, Zinn K . Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci. 2018; 19(4). PMC: 5979285. DOI: 10.3390/ijms19040925. View

20.

Tan D, Horning S, Hoppe R, Levy R, Rosenberg S, Sigal B . Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013; 122(6):981-7. PMC: 3739040. DOI: 10.1182/blood-2013-03-491514. View